Key result
A scalable, feeder-free method successfully differentiated human induced pluripotent stem cells into endocardial cells capable of undergoing endothelial-to-mesenchymal transition to generate cardiac valve cells.
Why the study?
Advancements in valve biology and novel therapeutics have been hindered by a lack of accessibility to human valve cells.
A novel feeder-free method to generate human endocardial and cardiac valve cells from iPSCs provides a scalable platform for studying valvular heart disease and biology.
Answers are grounded in this paper and cite their sources.
Scalable iPSC-derived endocardial cells now available; leaves open their role in valvular disease modeling and therapeutic screening.
Summary Valvular heart disease presents a significant health burden, yet advancements in valve biology and novel therapeutics have been hindered by the lack of accessibility to human valve cells. In this study, we have developed a scalable and feeder-free method to differentiate human induced pluripotent stem cells (iPSCs) into endocardial cells. Importantly, we show that these endocardial cells are transcriptionally and phenotypically distinct from vascular endothelial cells and can be directed to undergo endothelial-to-mesenchymal transition (EndMT) to generate cardiac valve cell populations. Following this, we identified two distinct populations—one population undergoes EndMT to become valvular interstitial cells (VICs), while the other population reinforces their endothelial identity to become valvular endothelial cells (VECs). Lastly, we confirmed the identities of our iPSC-derived cell populations and identified putative markers through transcriptomic analyses. By increasing the accessibility to these cell populations, we aim to accelerate discoveries for cardiac valve biology and disease.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) studied Valvular heart disease (in vitro modeling). Feeder-free monolayer differentiation with CHIR-99021, BMP10, and bFGF vs. VEGF-A (100 ng/mL) and bFGF (50 ng/mL) directed endothelial fate was evaluated on Generation of CD31+ endocardial population. A scalable, feeder-free method successfully differentiated human induced pluripotent stem cells into endocardial cells capable of undergoing endothelial-to-mesenchymal transition to generate cardiac valve cells.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: